和黄医药(0013.HK):出售非核心合资企业 赛沃替尼成功NDA

西南证券
03 Jan

事件:1 月1 日,和黄医药宣布达成两项协议,以6.08 亿美元 (人民币44.78亿元) 现金向金浦健服投资管理和上海医药出售上海和黄药业的45%的股权。1月2日,公司宣布赛沃替尼联合奥希替尼合疗法用于治疗伴有MET 扩增的一线EGFR 抑制剂治疗后进展的肺癌患者的中国新药上市申请获受理并获纳入优先审评。出售非核心合资企业,聚焦创新药物研发。上海和黄药业主要负责在中国生产、销售及分销其自有品牌...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10